Overview
Bethlem muscular dystrophy (also known as Bethlem myopathy or early-onset benign autosomal dominant limb-girdle myopathy with contractures) is a relatively mild form of collagen VI-related muscular dystrophy. It is caused by mutations in the COL6A1, COL6A2, or COL6A3 genes, which encode the three alpha chains of type VI collagen — a key structural protein found in the extracellular matrix of skeletal muscle and connective tissues. The disease primarily affects the skeletal muscular system, leading to progressive proximal muscle weakness and characteristic joint contractures, particularly of the fingers (long finger flexors), wrists, elbows, and ankles. Onset is variable but often occurs in early childhood, though some individuals may not be diagnosed until adulthood. Affected individuals typically present with mild to moderate proximal limb weakness, hypotonia in infancy, and slowly progressive contractures of multiple joints. A distinctive feature is the combination of distal joint hyperlaxity (especially in the fingers and wrists during childhood) with proximal joint contractures. Skin findings such as follicular hyperkeratosis (rough, bumpy skin on the arms and legs), keloid formation, and soft, velvety skin on the palms and soles may also be present. Most patients remain ambulatory into adulthood, though some may require assistive devices later in life. Respiratory function can decline slowly over decades, and a subset of patients may eventually require nocturnal ventilatory support. There is currently no cure or disease-specific treatment for Bethlem muscular dystrophy. Management is supportive and multidisciplinary, including physical therapy to maintain joint mobility and muscle strength, orthopedic interventions for contractures, and monitoring of respiratory function. Genetic counseling is recommended for affected families. Research into collagen VI biology and potential therapeutic strategies, including gene therapy approaches, is ongoing.
Also known as:
Clinical phenotype terms— hover any for plain English:
Autosomal dominant
Passed on from just one parent; each child has about a 50% chance of inheriting it
Variable
Can begin at different ages, from infancy through adulthood
Treatments
No FDA-approved treatments are currently listed for Bethlem muscular dystrophy.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for Bethlem muscular dystrophy at this time.
New trials open frequently. Follow this disease to get notified.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Bethlem muscular dystrophy.
Community
No community posts yet. Be the first to share your experience with Bethlem muscular dystrophy.
Start the conversation →Latest news about Bethlem muscular dystrophy
2 articlesCaregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Bethlem muscular dystrophy
What is Bethlem muscular dystrophy?
Bethlem muscular dystrophy (also known as Bethlem myopathy or early-onset benign autosomal dominant limb-girdle myopathy with contractures) is a relatively mild form of collagen VI-related muscular dystrophy. It is caused by mutations in the COL6A1, COL6A2, or COL6A3 genes, which encode the three alpha chains of type VI collagen — a key structural protein found in the extracellular matrix of skeletal muscle and connective tissues. The disease primarily affects the skeletal muscular system, leading to progressive proximal muscle weakness and characteristic joint contractures, particularly of th
How is Bethlem muscular dystrophy inherited?
Bethlem muscular dystrophy follows a autosomal dominant inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
Which specialists treat Bethlem muscular dystrophy?
2 specialists and care centers treating Bethlem muscular dystrophy are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.